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Serum amyloid P component (SAP, also known as Pentraxin 2; APCS gene) is a component of
the humoral arm of innate immunity involved in resistance to bacterial infection and reg-
ulation of tissue remodeling. Here we investigate the role of SAP in antifungal resistance.
Apcs−/− mice show enhanced susceptibility to A. fumigatus infection. Murine and human
SAP bound conidia, activate the complement cascade and enhance phagocytosis by neu-
trophils. Apcs−/− mice are defective in vivo in terms of recruitment of neutrophils and
phagocytosis in the lungs. Opsonic activity of SAP is dependent on the classical pathway of
complement activation. In immunosuppressed mice, SAP administration protects hosts
against A. fumigatus infection and death. In the context of a study of hematopoietic stem-cell
transplantation, genetic variation in the human APCS gene is associated with susceptibility to
invasive pulmonary aspergillosis. Thus, SAP is a fluid phase pattern recognition molecule
essential for resistance against A. fumigatus.
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The innate immune system represents the first line ofresistance against pathogens and a key determinant in theactivation and orientation of adaptive immunity through
the complementary activities of a cellular and humoral arm1.
Cell-associated innate immune molecules sense pathogen-derived
agonists leading to activation of different inflammatory
pathways2. Humoral pattern recognition molecules (PRMs) are
essential components of the innate immune response sharing
functional outputs with antibodies3, including opsonisation,
regulation of complement activation, agglutination, and
neutralization1. Humoral PRMs in turn interact with and regulate
cellular effectors1,3–6. Components of humoral innate immunity
include complement components, ficolins, collectins, and
pentraxins1,7,8.
Pentraxins are an ancient group of proteins evolutionarily
conserved from arachnids and insects to humans characterized by
the presence of a 200 amino acid (aa) pentraxin domain and a
pentraxin signature (HxCxS/TWxS, x= any aa)7,8. CRP (also
called PTX1) and SAP (PTX2; APCS gene) are the classic short
pentraxins. CRP and SAP are acute phase response proteins
produced in the liver in response to infection and inflammatory
cytokines8–10.
SAP has complex biological functions that include regulation of
matrix formation and resistance to infectious agents8,10. These
general functions are shared by other pentraxins11–14. SAP was
found to bind viruses (e.g., influenza)15, bacteria (e.g., Strepto-
coccus pneumoniae, Staphylococcus aureus, mycobacteria)16,17
and malaria parasites18. Pentraxins, including SAP, behave as
“ante-antibodies”, activating complement and interacting with
Fcγ receptors (Rs)1–3. SAP regulates complement activation by
interacting with C1q19, members of the ficolin family20 and the
complement regulator C4-binding protein (C4BP)21. Moreover
SAP interacts with FcγRs and has opsonic activity3,22–25. In
in vitro and in vivo models of infection, SAP has been reported to
have dual influence on antimicrobial resistance depending on the
species and experimental conditions. For instance, interaction of
SAP with S. pyogenes, Neisseria meningitides and some variants of
Escherichia coli led to decreased phagocytosis and killing by
macrophages and inhibition of complement activation26. Apcs−/−
mice showed better survival in experimental infections with S.
pyogenes and E. coli26.
SAP plays an important role in the regulation of extracellular
matrix deposition. SAP is an important component of amyloi-
dosis, where it promotes persistence of amyloid fibrils through
binding and consequent stabilization27,28. A specific antibody
against SAP promotes clearance of amyloid deposits in patients
with systemic amyloidosis29. Moreover, SAP has been shown to
inhibit lung fibrosis in preclinical models by regulating macro-
phage polarization30–33.
SAP has entered early clinical assessment for the treatment of
lung fibrosis10. In a randomized clinical trial, use of recombi-
nant and identical to the endogenous human SAP (PRM-151)
was associated with reduction in fibrocytes in pulmonary
fibrosis patients34. A Phase 2 study trial of PRM-151, a novel
anti-fibrotic immunomodulator, was reported in patients with
Idiopathic Pulmonary Fibrosis (IPF)35 and in a 28-week Phase
2 trial, infusions of SAP improved lung function36,37 by inhi-
biting alternative activation of macrophages and fibrocyte
differentiation31,32.
The distant relative of SAP, PTX3, has been shown to play an
essential role in resistance against A. fumigatus and related fungi.
Strong genetic evidence is also consistent with a key role of PTX3
in resistance against A. fumigatus in humans in different clinical
settings38–47. Given the PTX3 precedent, it was important to
assess the role of SAP in resistance against A. fumigatus. Here we
report that SAP was non-redundant for resistance against A.
fumigatus in mice. SAP-promoted phagocytosis of conidia
involved activation of the complement cascade. In immunosup-
pressed mice, SAP administration resulted in protection against
A. fumigatus. In the context of hematopoietic stem-cell trans-
plantation, the APCS locus emerged as a novel risk factor reg-
ulating susceptibility to invasive pulmonary aspergillosis (IPA).
Thus, SAP is a fluid phase PRM that plays an essential role in
resistance against A. fumigatus infection and has therapeutic
potential against fungal infections.
Results
SAP is essential for resistance to A. fumigatus infection. Apcs−/−
mice were used to assess the role of this molecule in resistance
against A. fumigatus pulmonary infection. As shown in Fig. 1a, b,
where two doses of conidia (1 × 108 or 5 × 107) were injected
intratracheally (i.t.), Apcs−/− mice showed increased susceptibility
to infection. Apcs−/− mice showed lethal infection with a median
survival time (MST) of 3 days compared to MST > 10 days of wt,
both when 1 × 108 (Fig. 1a) or 5 × 107 (Fig. 1b) conidia were used.
Actually, 89.9% (8/9) (Fig. 1a) and 44.4% (5/9) (Fig. 1b) of Apcs−/−
mice succumbed on day 3 compared to 23.8% (2/9) or 0% (0/6) of
wt mice. At the end of the experiment (monitoring until day 10),
11.1% (1/9) and 33.3% (3/9) of Apcs−/− mice survived to infection
compared to 55.6% (5/9) or 83.3% (5/6) of wt mice, at 1 × 108
(Fig. 1a) or 5 × 107 (Fig. 1b) conidia (P < 0.05). Figure 1 shows one
experiment out of 2 (1 × 108) or 5 (5 × 107) performed. Supple-
mentary Table 1 summarizes cumulative results obtained in
experiments using 5 × 107 conidia. Similar results were obtained in
pulmonary infections by different clinically relevant species of the
Trichocomaceae family, such as A. flavus (5 × 107) (Supplementary
Fig. 1) and A. terreus (1 × 108) (Supplementary Fig. 2). Although A.
terreus showed low pathogeniticy in mice even with the highest
dose of injected conidia (1 × 108), differences in survival (90.9%,
10/11 of survived wt mice at 1 × 108 conidia compared to 61.5%, 8/
13 of Apcs−/− mice; P= 0.09) (Supplementary Fig. 2a) and fungal
burden in the lung (P= 0.002) (Supplementary Fig. 2b) indicated
augmented susceptibility associated with SAP-deficiency. No rele-
vance of SAP was observed in a model of fungal dissemination
using Candida albicans (i.v., 5 × 106) (wt, 50.0% vs. Apcs−/−, 58.3%
of survived mice) (Supplementary Fig. 3).
In an effort to assess whether the phenotype observed in Apcs−/−
mice was indeed related to SAP deficiency48, recombinant murine
SAP was used. Pre-opsonisation of A. fumigatus conidia with
recombinant murine SAP rescued the susceptibility of Apcs−/−
mice to infection, without affecting the resistance of wt mice
(Fig. 1c). Indeed, 69% (9/13) of SAP-treated Apcs−/− mice resisted
to infection (MST > 10 days; P < 0.0001) compared to 0% (0/14) of
Apcs−/− mice treated with vehicle (MST 3 days). Survival was
similar in wt groups (wt: 80%, 8/10; MST > 10 days; SAP-treated wt:
70%, 7/10; MST > 10 days). Similar results were observed when
murine SAP (50 µg/mouse) was injected intravenously (i.v.)
(Fig. 1d).
SAP-deficiency was associated with defective recruitment of
neutrophils in response to A. fumigatus, as assessed by cell counts
(Supplementary Fig. 4a) (P= 0.008; 16 h) and levels of myelo-
peroxidase (MPO) (Apcs−/−, 449 ± 28 vs. wt, 564 ± 16 ng/ml;
P= 0.008; 16 h) in bronchoalveolar lavage fluids (BALFs)
(Supplementary Fig. 4b), and lower levels of C5a (Apcs−/−,
22.7 ± 1.7 vs. wt, 31.5 ± 1.8 ng/ml; P= 0.004; 16 h) (Supplemen-
tary Fig. 4b). Decreased C3d in lung lysates was also observed
(P= 0.03) (Supplementary Fig. 4c). Murine SAP pre-opsonisation
restored the levels of MPO and the number of neutrophils in
BALFs of Apcs−/− mice (16 h) (Supplementary Fig. 5), hence
suggesting that SAP-opsonized conidia trigger an inflammatory
response in the lung essential for resistance to fungus.
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Mechanism of SAP-mediated resistance to A. fumigatus.
Injection of A. fumigatus conidia increased the circulating levels
of SAP (0.55 ± 0.43 µg/ml; n= 3) at 4 (2.63 ± 1.02 µg/ml, n= 4)
and 16 h (22.12 ± 8.50 µg/ml, n= 3) comparably to those
observed after LPS administration (28.47 ± 11.43 µg/ml, n= 3;
LPS, 0.8 mg/kg, 16 h) (Fig. 2a). In lungs (n= 3; 4 h), SAP loca-
lized in areas of cell recruitment and complement deposition
closely associated with conidia (Fig. 2b).
Neutrophils are major players of resistance against A.
fumigatus49. Therefore, we examined neutrophil phagocytosis of
A. fumigatus in BALFs of Apcs−/− mice. As shown in Fig. 2c, d, in
the lungs of Apcs−/− mice we observed a 6-fold increase of A.
fumigatus CFU [Apcs−/−, median, 1.9 × 108, interquartile range
(IQR) 3.0 × 108−1.6 × 108 vs. wt, 4.0 ± x 107, IQR 6.8 × 107−4.5 ×
107; P < 0.0001] (Fig. 2c) and reduced phagocytosis by neutrophils
(Apcs−/−, 28.74 ± 3.96% vs. wt, 42.53 ± 6.39%; P= 0.05) (Fig. 2d).
Based on these in vivo results, the interaction of SAP with
conidia and its impact on phagocytosis and complement
activation was examined in vitro. Recombinant murine SAP
bound viable dormant, swollen and germinated conidia, as
assessed by FACS (Fig. 2e) and microscopy (Fig. 2f). A similar
binding was observed for A. flavus and A. terreus, but not for
Candida albicans (Supplementary Fig. 6a–c). Binding on A.
fumigatus was competed by human SAP, but not by CRP
(Fig. 2e). Similarly, PTX3 competed binding (Supplementary
Fig. 6d), thus indicating that the binding site(s) on A. fumigatus is
(are) conserved between mouse and human SAP and PTX3.
In whole blood, phagocytosis by neutrophils was reduced in
Apcs−/− mice, both at 1 (wt, 47.0 ± 4.0 vs. Apcs−/−, 41.3 ± 2.4%;
P= 0.05) and 20 min (wt, 55.7 ± 3.1 vs. Apcs−/−, 44.4 ± 2.3%;
P= 0.01) after incubation with A. fumigatus conidia (Fig. 2g).
Hence, SAP basal levels would be sufficient to affect conidia
phagocytosis. Murine SAP pre-opsonisation rescued the defect
(1 min, P= 0.002; 20 min, P= 0.03) and potentiated phagocytosis
by wt neutrophils (1 min, P < 0.0001; 20 min, P= 0.03) (Fig. 2g).
Similar results were obtained when human native SAP was used
(Supplementary Fig. 7). In addition, membrane expression of
CD11b in wt neutrophils was reduced from 97.2 ± 0.4% to 52.5 ±
3.8% and 47.4 ± 2.8%, respectively, at 1 and 20 min after exposure
to A. fumigatus (Fig. 2h). In neutrophils from Apcs−/− mice, the
decrease in CD11b expression was minor (basal, 97.0 ± 0.5%;
1 min, 59.6 ± 2.4%, P= 0.07; 20 min 57.7 ± 2.2%, P= 0.004), as a
consequence of an accumulation of CD11b in the phagocytic cup
associated with phagocytosis3,50,51. Murine SAP pre-opsonisation
restored CD11b internalization and increased it in wt (Fig. 2h).
Therefore, SAP acts as an opsonin for early disposal of A.
fumigatus by neutrophils, enhancing phagocytic activity.
The classical and lectin pathways are main initiators of
complement activation against A. fumigatus52. Experiments of
opsonophagocytosis were therefore performed in the presence
of human or mouse sera deficient for different complement
components to define the molecular mechanism responsible for
SAP-mediated resistance to A. fumigatus. Phagocytosis by
human neutrophils was abolished in serum depleted for C3
(−72.0 ± 4.7%, P < 0.0001), C1q (−85.3 ± 0.7%, P < 0.0001) and
MBL (−91.7 ± 1.9%, P < 0.0001) compared to normal serum,
thus indicating importance of both the classical and the MBL-
mediated lectin pathway in resistance against this fungus. In
Fig. 1 Susceptibility of Apcs−/− mice to A. fumigatus. a, b Percent survival of wt and Apcs−/− mice after i.t. injection of 1 × 108 (a) or 5 × 107
(b) A. fumigatus (AF) conidia; wt, n= 9 (a) or n= 6 (b); Apcs−/−, n= 9 (a, b). a *P= 0.02; b P= 0.05 (Log-rank, Mantel-Cox test). c, d Rescue of
susceptibility to A. fumigatus in Apcs−/− mice. c Injection of non-opsonised or murine SAP(Sap)-opsonised AF conidia (5 × 107). wt, n= 10; wt+ Sap,
n= 10; Apcs−/−, n= 14; Apcs−/−+ Sap, n= 13. ****P < 0.0001, wt vs. Apcs−/− or Apcs−/− vs. Apcs−/−+ Sap (Log-rank, Mantel-Cox test). d 5 × 107 and
i.v. injection of Sap (50 µg/mouse). wt, n= 10; wt+ Sap, n= 10; Apcs−/−, n= 13; Apcs−/−+ Sap, n= 10. **P= 0.03, wt vs. Apcs−/−; *P= 0.05, Apcs−/−
vs. Apcs−/−+ Sap (Log-rank, Mantel-Cox test).
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two independent experiments using 5 and 10% of sera,
opsonisation with human native SAP potentiated phagocytosis
in normal (serum 5%, % of increase, 37.4 ± 10.3%, P= 0.009;
serum 10%, 18.3 ± 2.0%, P= 0.01) and MBL-depleted serum
(5%, 55.5 ± 17.0%; 10%, 19.8 ± 6.1%, P= 0.04), but not in
sera depleted for C3 and C1q (Fig. 3a). Similarly, as assessed
in independent experiments, neutrophil phagocytosis was
reduced in whole blood of C3−/− (−43.4 ± 10.8%, P= 0.02),
C1q−/− (−47.1 ± 11.4%, P= 0.02) and Mbl1/2−/− (−40.2 ±
12.3%, P= 0.01) mice compared to wt, but not in Fb−/− mice
(Fig. 3b). Pre-opsonization with murine SAP potentiated
phagocytosis in wt [% of increase, 30.8 ± 5.4% (Fig. 3b, left);
94.3 ± 48.2%, P= 0.004 (Fig. 3b, middle); 134.7 ± 45.2%,
P= 0.02 (Fig. 3b, right)], Mbl1/2−/− (68.6 ± 28.3%, P =
0.002) and Fb−/− (196.6 ± 61.8%, P= 0.005)] but not in
C3−/− and C1q−/− mice (Fig. 3b). These results indicate that
the interaction with the classical complement pathway is
required for the initiation of SAP-mediated phagocytosis, with
no relevance of the alternative pathway. In agreement, a
decreased C1q deposition on A. fumigatus conidia was
observed after incubation with plasma from Apcs−/− mice
(P= 0.05) (Fig. 3c). Moreover, while MBL in serum plays a role
Fig. 2 SAP acts as opsonin for phagocytosis of A. fumigatus. a Induction of SAP levels in mice after i.t. injection of 5 × 107 AF conidia; −, sham mice; LPS,
0.8 mg/kg. Mean ± SD of an independent experiment; n= 3, −; n= 4, AF 4 h; n= 3, AF 16 h; n= 3, LPS. b Confocal images depicting SAP localization in
infected lung (4 h; 5 × 107 fluorescein (FITC)-labeled AF conidia; n= 3 mice). Left, merged image of a lung stained for SAP (red), C3 (blue) and neutrophils
(Ly6G+ cells; cyan). Conidia are evident from the detection of FITC (green) signal. Dashed white arrowheads indicate regions of SAP localization on AF
conidia. A representative staining of lung of a non-infected mouse is also shown (basal; left box). Middle, close-up image of the white dashed region (left)
showing SAP localization on AF. The image refers to extracted AF and SAP signals also separately shown in the boxes within the image. Right, a section of
infected lung of Apcs−/− mouse is also shown. Scale bar, 50 µm. c Number of CFU per lung at 16 h after infection with 5 × 107 conidia. Each spot
corresponds to a single mouse (wt, n= 9; Apcs−/−= 11). One experiment out of 2 performed with similar results. Mean ± SEM. P < 0.0001 (two-sided,
Mann–Whitney U-test). d FACS analysis of in vivo phagocytosis in BALF neutrophils 4 h after injection of 5 × 107 FITC-labeled AF conidia. The figure shows
results of two pooled experiments with n= 10 wt and n= 9 Apcs−/− mice. Mean ± SEM. *P= 0.05 (two-sided, unpaired t-test). e, f Interaction of SAP with
A. fumigatus. e FACS analysis of binding of biotin-conjugated (b-) murine SAP (Sap; 10 µg/ml) to viable dormant or germinating conidia of AF (1 × 108).
Human SAP (50 µg/ml) and CRP (50 µg/ml) were also used. Mean ± SD of one quadruplicate experiment of two performed. f b-Sap (10 µg/ml) interaction
with AF. Images refer to maximum intensity projection of z-stacks. Scale bar, 5 µm. g, h Effect of SAP on A. fumigatus phagocytosis by neutrophils.
g, h FACS analysis (one experiment shown out of 3 performed) of phagocytosis (g) and CD11b internalization (h) in neutrophils after challenge with FITC-
labeled AF conidia (1 × 107/200 µl of blood) opsonized or not with murine SAP is shown. g neutrophil phagocytosis in whole blood of wt and Apcs−/− mice.
h CD11b expression in neutrophils of g. g, h n= 12 wt and n= 11 Apcs−/− mice. Mean ± SEM. g 1 min, *P= 0.05; ***P= 0.002; ****P < 0.0001. 20min,
*P= 0.01, wt vs. Apcs−/−; *P= 0.03 wt vs. wt+ Sap or Apcs−/− vs. Apcs−/−+ Sap. h 1 min, *P= 0.01; ***P= 0.0004; ****P < 0.0001; 20min, *P= 0.04;
***P= 0.004. g, h (two-sided, unpaired t-test).
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Fig. 3 Initiation of classical complement activation at the bases of SAP-mediated phagocytosis. a FITC-labeled AF conidia (1.6 × 106) phagocytosis by
freshly isolated human neutrophils (2 × 105) in presence of sera depleted (−) of complement components and the effect of human SAP opsonisation after 1 and
30min. AF conidia (2 × 108) opsonisation with 100 µg of human native SAP. Five percent (left) or 10% (right) of human sera were used. Mean ± SEM of two
experiments performed in triplicate and merged. Each spot corresponds to a replicate. Left, NS vs. NS+ SAP, **P=0.009; ***P=0.002. MBL− S vs. MBL− S+
SAP, ***P=0.002 (two tailed, Mann–Whitney U-test). Right, NS vs. NS+ SAP, *P=0.01; ***P=0.002. MBL- S vs. MBL- S+ SAP, *P=0.04 (two tailed,
Mann–Whitney U-test). b FACS analysis of phagocytosis of FITC-labeled AF conidia (5 × 106/200 µl of blood; 20min) opsonized or not with murine SAP in
whole blood of wt, C3-, C1q-, MBL1/2-, and Factor B-deficient mice. Each figure refers to independent experiments performed. Results of C3−/−, C1q−/−,
and Mbl1/2−/− are mean ± SEM of one experiment, whereas for Fb−/− two experiments were merged. Correspondent wt littermates were used as control
for C1q-, MBL1/2- (C57BL/6J) and Factor B-deficient mice (C57BL6/NJ). Each spot represents a single mouse. Left, n= 11 wt, n= 10 C3−/−, n= 8 C1q−/−. wt vs.
C3−/−, *P=0.02; wt vs. C1q−/−, *P=0.02 (two-sided, unpaired t-test). Middle, n= 5 wt, n= 5 Mbl1/2−/−. wt vs. Mbl1/2−/−, *P=0.01; wt vs. wt+ Sap,
***P=0.004;Mbl1/2−/− vs.Mbl1/2−/−+ Sap, ***P=0.002 (two-sided, unpaired t-test). Right, n= 12 wt, n= 14 Fb−/−. wt vs. wt+ Sap, *P=0.02 (two-sided,
unpaired t-test); Fb−/− vs. Fb−/− + Sap, **P=0.005 (two tailed, Mann–Whitney U-test). c FACS analysis of C1q deposition on AF conidia (1 × 107) in presence
of plasma from wt (n= 9) or Apcs−/− (n= 7) mice. Mean ± SEM; *P=0.05 (two-sided, unpaired t-test). d Effect of blocking of Fcγ receptors in SAP-mediated
phagocytosis. Human SAP-pre-opsonized FITC-labeled AF conidia (1.6 × 106) phagocytosis by freshly isolated human neutrophils (2 × 105; 5min) in presence of
NS and anti-CD16, anti-CD32, anti-CD64 or an irrelevant mouse IgG1 (all used at 10 µg/ml). Each spot corresponds to a single healthy donor (n= 4) performed
in duplicate. Mean ± SEM. e–g Effect of IgG depletion in SAP-mediated phagocytosis (f) and complement deposition (g). e Western blot analysis for SAP and
IgGs in human plasma and after their depletion. 1 µl/lane of plasma-heparin from five healthy donors (A–E) and 10 µg/lane of proteins eluted from the anti-SAP
column were loaded. Ponceau red staining was shown. Human SAP (0.1 µg/lane) was used as control. f FACS analysis of phagocytosis by neutrophils (2 × 105)
isolated from A–E donors after challenge with FITC-labeled AF conidia (1.6 × 106) opsonized or not with human SAP (100 µg/1 × 109 conidia/ml) in the presence
of autologous plasma-heparin (10%) depleted of SAP (SAP-) and IgGs (IgG-). g C3 deposition on AF conidia (1 × 107) opsonized or not with human SAP. SAP-
and IgG-depleted plasma-heparin (10%) from A–E donors were used. f, g Each spot refers to mean of a duplicate per donor. Mean ± SEM.
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in opsonisation, MBL and ficolins, the latter ascertained using
specific antibodies (Supplementary Fig. 8), are dispensable for
SAP-mediated enhanced phagocytosis.
It was important to assess whether the opsonic activity of SAP
was dependent on FcγR or IgG. SAP-mediated opsonophagocy-
tosis did not involve engagement of FcγRs, as ascertained in
phagocytosis experiments with specific blocking antibodies
(Fig. 3d). As control51, PTX3-mediated phagocytosis was inhibited
by FcγRII blockage (Fig. 3d). Depletion of IgGs from the plasma
of healthy donors (n= 5) (Fig. 3e) resulted in decreased
neutrophil phagocytosis at the 20min time-point (−26.6 ± 3.3%,
P= 0.0006) compared to control plasma. A similar reduction was
observed when plasma depleted from SAP (Fig. 3e) was used
(1min, −1.65 ± 13.7%, P= 0.28; 20min, −20.5 ± 5.9%, P= 0.04).
Human SAP pre-opsonization rescued and potentiated neutrophil
phagocytosis in IgG-depleted (% of increase, 1 min, 59.6 ± 19.5%,
P= 0.04; 20 min, 95.6 ± 14.6%, P= 0.0007), SAP-depleted (1 min,
84.1 ± 26.9%, P= 0.008; 20min, 127.1 ± 34.1%, P= 0.02) and
normal (1 min, 92.0 ± 24.7%; 20 min, 87.9 ± 17.9%, P= 0.008)
plasma (Fig. 3f), thus indicating that SAP-mediated opsonopha-
gocytosis did not involve an antibody-mediated engagement of
FcγR.
SAP induced complement activation on A. fumigatus culmi-
nating in the formation of the membrane attachment complex
(MAC; C5b-C9). In plasma of Apcs−/− mice, decreased C3
deposition was observed on A. fumigatus conidia in vitro (Fig. 4a).
Pre-opsonisation of A. fumigatus with recombinant murine SAP
rescued and increased C3 deposition in Apcs−/− and wt plasma,
respectively (Fig. 4a). In the same experiment, a decreased C5a
formation was observed in plasma of Apcs−/− compared to wt
mice (1 min, 8.5 ± 2.1 vs. 13.0 ± 4.5 ng/ml; 5 min, 14.2 ± 4.3 vs.
35.7 ± 6.9 ng/ml, P= 0.008; 10 min, 26.5 ± 2.2 vs. 53.2 ± 7.5 ng/
ml, P= 0.003; 20 min, 61.5 ± 7.8 vs. 113.8 ± 15.5 ng/ml, P= 0.005,
respectively, Apcs−/− vs. wt) (Fig. 4b). This defect was rescued by
murine SAP opsonisation (1 min, P= 0.003; 5 min, P= 0.007;
10 min, P= 0.002; 20 min, P= 0.04), which also increased C5a in
wt plasma (Fig. 4b). Assembly of MAC on the surface of A.
fumigatus conidia was decreased in sera depleted for C3 (1 min,
−72.2 ± 4.8%; 30 min, −73.0 ± 10.1%; Mean ± SD; P < 0.0001),
C1q (1 min, −81.8 ± 3.6%; 30 min, −68.5 ± 4.0%; P < 0.0001),
MBL (1 min, −92.2 ± 2.8%, P < 0.001; 30 min, −84.5 ± 3.0%, P <
0.0001) and FB (1 min, −80.6 ± 5.2%; 30 min, −46.4 ± 1.0%; P <
0.0001) and increased in FH-depleted serum (1 min, +5.6 ±
15.8%; 30 min, +55.0 ± 24.9%, P < 0.005). Pre-opsonisation with
human SAP enhanced MAC formation on conidia both at 1 min
(P= 0.001) and at 30 min (P= 0.008) in the presence of normal
serum and in those depleted of MBL, FB, and FH, but not in
serum depleted for C1q (Fig. 4c). As assessed in a resazurin-based
cell viability assay, pre-opsonisation of human SAP resulted in
increased microbicidal activity of A. fumigatus conidia in normal
serum and in serum depleted of MBL (Fig. 4d). The effect was
abolished in human sera depleted of C3 or C1q. Posaconazole
Fig. 4 SAP-mediated complement activation on A. fumigatus. a FACS analysis (frequency, left; MFI, right) of C3 from wt (−, n= 10; + Sap, n= 10) and
Apcs−/− (−, n= 10; + Sap, n= 10) mouse plasma on AF conidia (1 × 107) opsonized or not with murine SAP. a Left, wt vs. Apcs−/−, *P= 0.01 (1 min),
*P= 0.02 (5 min), ***P= 0.003 (10min), **P= 0.007 (20min). wt vs. wt+ Sap, *P= 0.02 (1 min). Apcs−/− vs. Apcs−/−+ Sap, **P= 0.008 (1 min),
***P= 0.003 (5 min), *P= 0.05 (10min), *P= 0.05 (20min) (two-sided, unpaired t-test). a Right, wt vs. Apcs−/−, ***, P= 0.002 (10 min), **P= 0.006
(20min). wt vs. wt+ Sap, *P= 0.01 (1 min), **P= 0.005 (5min). Apcs−/− vs. Apcs−/−+ Sap, ***P= 0.0003 (1 min), ***P= 0.002 (5min), *P= 0.04
(10min and 20min) (two-sided, unpaired t-test). b Murine plasma C5a levels after incubation with AF conidia shown in a. n= 11 mice/genotype. wt vs.
Apcs−/−, **P= 0.008 (5 min), ***P= 0.003 (10min), **P= 0.005 (20min). wt vs. wt+ Sap, **P= 0.009 (20min). Apcs−/− vs. Apcs−/−+ Sap,
***P= 0.003 (1 min), **P= 0.007 (5 min), ***P= 0.002 (10min), *P= 0.04 (20min) (two-sided, unpaired t-test). a, b A representative independent
experiment shown out of 3 performed. Each spot represents plasma from a single mouse. a, b Mean ± SEM. c FACS analysis of SAP-mediated MAC
deposition on AF conidia (1 × 107) in the presence of human sera depleted of complement components. Mean ± SEM of two experiments in quadruplicate
and merged out of 4 performed. Each spot corresponds to a replicate. NS vs. NS+ SAP, ***P= 0.001; **P= 0.008 (two-sided, unpaired t-test). MBL− S vs.
MBL− S+ SAP, **P= 0.006; ***P= 0.003 (two-sided, unpaired t-test). FB− S vs. FB− S+ SAP, ***P= 0.002; **P= 0.009 (two-sided, unpaired t-test).
d Quantitative analysis of AF viability performed using a resazurin-based assay. AF viability assay performed in sera depleted of complement components.
Results are mean ± SEM of the relative fluorescence intensity. Effect of Posaconazole (POC; 1 µM) exposure is also shown. Figure summarizes one
experiment out of 5 performed with n= 5 replicates each. *P= 0.01; **P= 0.009 (two-sided, unpaired t-test).
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(POC) was used as antifungal control (Fig. 4d). Actual fungal
killing was also ascertained as CFU counts (Supplementary
Fig. 9). SAP-mediated complement activation on A. fumigatus
was antibody-independent. Decreased C3 deposition was
observed in IgG-depleted plasma, both at 1 (−53.5 ± 7.9%,
P= 0.02) and 20 min (−74.2 ± 4.7%, P= 0.002) compared to
control. In SAP-depleted plasma, reduction of C3 deposition
corresponded to −30.5 ± 9.1%, (1 min, P= 0.025) and −58.6 ±
4.9%, (20 min, P < 0.0001). Pre-opsonisation with human SAP
rescued and increased C3 deposition in both IgG- (% of increase,
1 min, 87.9 ± 25.2%, P= 0.022; 20 min, 139.6 ± 14.6%, P < 0.0001)
and SAP-depleted (1 min, 14.3 ± 4.4%; 20 min, 144.5 ± 23.8%,
P= 0.001) plasma as well as in the control (1 min, 75.0 ± 43.4%;
20 min, 36.1 ± 13.3%, P= 0.008) (Fig. 3g), thus suggesting an
effect of SAP in promoting complement activation on A.
fumigatus under mimed immunosuppressive conditions of anti-
body deficiencies.
Having found that SAP plays a non-redundant role in resistance
to A. fumigatus and that neutrophils were involved, it was important
to explore the role and significance of other phagocytic cell
populations using in vitro, ex vivo and in vivo approaches. As shown
in Fig. 5a, in a whole blood assay, in vitro SAP increased the
phagocytic activity of neutrophils [% of increase, wt, 134.3 ± 19.6%,
P < 0.0001 (1min); 103.8 ± 25.4%, P= 0.003 (20min); Apcs−/−,
176.3 ± 34.2%, P= 0.0004 (1min); 110.3 ± 311.0%, P < 0.0001
(20min)] and monocytes [wt, 138.2 ± 12.7%, P < 0.0001 (1min);
83.1 ± 14.5%, P= 0.002 (20min); Apcs−/−, 104.4 ± 20.9%, P= 0.005
(1min); 148.3 ± 23.7%, P < 0.0001 (20min)], but not of DC (Fig. 5a).
Similar results were obtained with human myelomonocytic cells
in vitro (30min; P= 0.03) (Fig. 5b).
Bone marrow-derived myelomonocytic cells were used to
further investigate the impact of SAP on this compartment. In the
presence of correspondent serum (10%), bone marrow-derived
macrophages obtained from Apcs−/− mice produced decreased
levels of CXCL1 (Apcs−/−, 7.5 ± 2.0 vs. wt, 8.6 ± 1.1 ng/ml),
CXCL2 (Apcs−/−, 15.6 ± 7.2 vs. wt, 29.8 ± 3.7 ng/ml), TNF-α
(Apcs−/−, 3.7 ± 0.6 vs. wt, 4.5 ± 0.4 ng/ml), IL-6 (Apcs−/−, 3.1 ±
0.8 vs. wt, 4.7 ± 0.9 ng/ml) after stimulation with A. fumigatus
conidia (24 h) (Fig. 5c).
We next investigated the impact of the Apcs deficiency on
macrophage and DC function in vivo. As assessed by FACS,
injection of conidia pre-opsonized with murine SAP increased
phagocytosis (4 h) in BALF macrophages (% of increase, wt,
41.8 ± 3.4%, P= 0.004; Apcs−/−, 26.8 ± 5.0%, P= 0.03) and
neutrophils (wt, 81.5 ± 32.6%, P= 0.03; Apcs−/−, 285.9 ± 60.2%,
P= 0.0003) derived from wt and Apcs−/− mice, but not in DCs
(Fig. 5d). SAP-deficiency did not affect phagocytosis in BALF
macrophages (51.4 ± 4.9 vs. 51.0 ± 14.1%; Apcs−/ vs. wt) and DCs
(7.8 ± 1.5 vs. 11.2 ± 3.4%; P= 0.18), but reduced it in neutrophils
(8.1 ± 2.5 vs. 16.0 ± 3.7%, Apcs−/ vs. wt, % of decrease: −49.2 ±
15.5%; P= 0.05) (Fig. 5d). In conclusion, although SAP facilitates
recognition, phagocytosis and functional responses by macro-
phages, the predominant effector cells affected by Apcs deficiency
in vivo are neutrophils.
Collectively, these results indicate that SAP-mediated resis-
tance against A. fumigatus involves complement-mediated
opsonization, neutrophil phagocytosis and pathogen killing.
Therapeutic potential of SAP. Having established that SAP is an
essential component of resistance to A. fumigatus, it was
important to obtain indications as to its therapeutic potential.
A. fumigatus infection is a clinical challenge in patients with
congenital or acquired immune deficiency. The most important
risk factor for IPA is represented by neutropenia and mono-
cytopenia that occur in immune-compromised patients40. The
potential therapeutic effect of SAP was determined in transiently
myelosuppressed mice. Therefore, we used a model of
cyclophosphamide-induced immune suppression to obtain indi-
cations as to the therapeutic potential of SAP. Dosage of
A. fumigatus conidia was newly optimized in mice after 2-day
treatment with cyclophosphamide (150 mg/kg). Human native
SAP (4 mg/kg) was injected intraperitoneally (i.p.) at 2 and 24 h
after infection. Immune-compromised mice did not survive
infection with 5 × 107 (17/17; MST 4 days), 1 × 107 (7/7; MST
4 days) and 5 × 106 (8/8; MST 5 days) conidia (Fig. 6a). SAP
protected immune-compromised mice increasing survival to 20%
(5 × 107; 12/15, MST 4; P= 0.002), 62.5% (1 × 107; 3/8, MST > 10;
P= 0.001) and 80% (5 × 106; 2/10, MST > 10; P= 0.004),
respectively (Fig. 6a). A 12-fold reduction in fungal burden was
observed in the lungs of SAP-treated mice 16 h after infection
with 1 × 107 conidia (median 2.0 × 106 CFU, IQR 9.0 × 106−8.0 ×
106 vs. 4.4 × 107 CFU, IQR 9.1 × 107−7.5 × 107; P= 0.02)
(Fig. 6b). Similarly, SAP (50 µg/mouse) administered i.t. 2 h after
infection (5×106 conidia) protected immune-compromised mice.
2/13 untreated mice survived (15.4%; MST 7 days), whereas 9/12
SAP-treated mice survived (75.0%; MST > 10; P= 0.003)
(Fig. 6c). I.t. SAP treatment resulted in a 23-fold reduction of lung
CFU 16 h after infection (median 2.3 × 104, IQR 1.1 × 105−1.0 ×
105 vs. 5.3 × 106, IQR 9.5 × 106−7.7 × 106; P= 0.008) (Fig. 6d).
Genetic variation in human SAP influences the risk of IPA. In
view of the critical role of SAP during fungal infection in vivo, we
next investigated the relationship between genetic variation in the
human APCS gene and susceptibility to IPA in patients at-risk.
For such, we assessed the cumulative incidence of IPA in patients
from the IFIGEN cohort undergoing allogeneic hematopoietic
stem-cell transplantation (Supplementary Table 2) according to
recipient or donor APCS genotypes of the single nucleotide
polymorphisms (SNPs) rs2808661 and rs3753869 (Table 1).
These SNPs were selected based on their ability to tag sur-
rounding variants with a pairwise correlation coefficient r2 of at
least 0.80 and a minor allele frequency ≥5%, covering therefore
the whole genetic variability across the APCS locus (Supple-
mentary Fig. 10).
The rs2808661 SNP in the donor genome was associated with
an increased risk of IPA after transplantation, whereas recipient
rs2808661 displayed a trend towards increased risk (Fig. 7a). The
cumulative incidence of IPA for donor rs2808661 was 23% for
GG, 21% for GA (P= 0.67) and 56% for AA genotypes (P= 0.04),
whereas for recipient rs2808661, the cumulative incidence ranged
from 20% for GG to 25% for GA (P= 0.58) and 36% for AA
(P= 0.08) (Fig. 7a). Upon modeling a dominant mode of
inheritance, the key contribution of the donor AA genotype to
the risk of infection was confirmed. As for the rs3753869 SNP,
association with risk was only detected in donor genomes (Fig. 7b).
The cumulative incidence of IPA was 21% for CC, 26% for CA
(P= 0.30) and 43% for AA genotypes (P= 0.03), respectively.
In a multivariate model accounting for age, gender, type of
transplantation, acute graft-versus-host disease (GVHD) and
antifungal prophylaxis, the AA genotype in rs3753869 conferred a
3.6-fold increased risk of developing IPA (Table 2). Collectively,
these results highlight genetic variation at the APCS locus as a
novel risk factor regulating susceptibility to IPA.
To assess whether genetic variation at the APCS locus was
associated with different SAP levels, this pentraxin was measured
in samples from hematological patients from the FUNBIOMICS
cohort53. SAP serum levels were similar in IPA patients (18.6 ±
1.2 µg/ml, n= 20) compared to controls (16.6 ± 1.3 µg/ml, n= 14;
P= 0.2), whereas higher amounts were present in BALFs (65.7 ±
26.4 ng/ml, n= 9; vs. 2.6 ± 0.7 ng/ml, n= 7; P= 0.0007) (Fig. 7c).
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Once analyzed for the single donor genotype, SAP concentration
in sera was to 18.8 ± 1.7 µg/ml for GG (n= 12), 23.7 ± 0.5 µg/ml
for GA (n= 3) and 14.7 ± 0.9 µg/ml for AA (n= 4; P= 0.103, AA
vs. GG; P= 0.0006, AA vs. GA; P= 0.05, AA vs. GG+GA) in
donor rs2808661 (Fig. 7d). Regarding donor rs3753869, SAP
concentration was 19.1 ± 1.3 µg/ml for CC (n= 13), 23.17 ±
2 .7 µg/ml for CA (n= 3) and 13.3 ± 2.9 µg/ml for AA (n= 4;
P= 0.03, AA vs. CC; P= 0.06, AA vs. CA; P= 0.02, AA vs. CC
+CA) (Fig. 7e). No differences were observed for GG vs. GA and
CC vs. CA, respectively, in recipient rs2808661 and rs3753869
(Supplementary Fig. 11). Therefore, the increased risk of IPA
according to donor APCS rs2808661 and rs3753869 genotypes is
associated with lower serum levels of SAP.
Discussion
The results presented here show that SAP is an essential com-
ponent of resistance against the fungal pathogen A. fumigatus.
Fig. 5 Effects of SAP on myelomonocytic cell function. a FACS analysis of phagocytosis (1 and 20min) of FITC-labeled AF conidia opsonized with murine SAP
by peripheral murine neutrophils (Ly6G+ CD11b+), monocytes (Ly6C+ CD11b+) and DCs (CD11c+) (1 × 107 conidia/200 µl of blood). N= 7 wt, n= 8 Apcs−/−.
wt vs. wt+ Sap, ****P< 0.0001 (1min), ***P=0.003 (20min) (neutrophils); ****P< 0.0001 (1min), ***P=0.002 (20min) (monocytes). Apcs−/− vs. Apcs−/− +
Sap, ***P=0.0004 (1min), ****P<0.0001 (20min) (neutrophils); **P=0.005 (1min), ****P<0.0001 (20min) (monocytes) (two-sided, unpaired t-test).
b Effect of human SAP opsonisation on in vitro phagocytosis by isolated human monocytes (n= 4 donors) (1 × 105 cells and 1 × 106 FITC-labeled AF conidia;
30min; 10% of autologous serum). *P=0.03 (two-sided, unpaired t-test). c Levels of CXCL1, CXCL2, TNF-α, and IL-6 in supernatants of bone marrow-derived
macrophages from wt and Apcs−/− mice stimulated (24 h) with A. fumigatus conidia (ratio 1:5, cell:conidia) in the presence of correspondent mouse serum (10%).
LPS, 10 ng/ml. n=4 mice per genotype. d FACS analysis of FITC-labeled AF conidia phagocytosis by neutrophils (CD45+ Ly6G+), macrophages (CD45+ Ly6C+
F4/80+) and DCs (CD45+ CD11c+) collected from BALFs of wt (−, n= 7; Sap, n= 5) and Apcs−/− (−, n= 8; Sap, n= 5) mice after i.t. injection of 5 × 107 conidia
(4 h) opsonized with murine SAP. d Neutrophils, wt vs. Apcs−/−, *, P=0.05; wt vs. wt+ Sap, *, P=0.03; ***, P=0.0003. Macrophages, *P=0.030;
***P=0.004 (two-sided, unpaired t-test). a–d Each spot corresponds to a single mouse (a, c, d) or single healthy donor (b). a–d Mean ± SEM of independent
experiments.
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Apcs−/− mice showed increased susceptibility to infection by
A. fumigatus, a phenotype rescued by in vitro opsonization of
fungi or in vivo administration of murine SAP. In vitro and
in vivo observations suggest that complement activation following
fungal recognition and phagocytosis of opsonized fungi are
responsible of SAP-mediated resistance.
SAP has been shown to bind a variety of microbial species and to
have opsonic activity16,19,22–24,26, though under selected conditions,
inhibition of phagocytosis has been reported26,54. Recently, SAP was
found to bind amyloid fibrils produced on the surface of Candida
albicans and to dampen recognition by the innate immune system55.
Here, we found that SAP binds A. fumigatus conidia and facilitates
phagocytosis, and evidence suggests that this pathway underlies the
role of this fluid phase PRM in resistance to this fungus.
The role of SAP in resistance to A. fumigatus is reminiscent of
findings with the related molecule PTX338. Genetic evidence in
Fig. 6 Therapeutic efficacy of SAP against invasive aspergillosis in immunosuppressed hosts. a Percent survival of transiently immunosuppressed wt
mice after i.t. injection with the indicated doses of AF conidia. The curve of untreated mice (n= 3) with cyclophosphamide is also shown. Human SAP
(4mg/kg) was i.p. injected at 2 h and 24 h after infection. AF 5 × 107, n= 17 mice; AF 5 × 107+ SAP, n= 15 mice; AF 1 × 107, n= 7 mice; AF 1 × 107+ SAP,
n= 8 mice; AF 5 × 106, n= 8 mice; AF 5 × 106+ SAP, n= 10 mice. An independent experiment shown. SAP-treated vs. saline, P= 0.002, AF 5 × 107;
P= 0.001, AF 1 × 107; P= 0.004, AF 5 × 106 (Log-rank, Mantel-Cox test). b Lung CFU in mice treated with cyclophosphamide and infected with 1 × 107 AF
conidia. N= 5 AF, n= 5 AF+ SAP. Mean ± SEM of an independent experiment. *P= 0.02 (two-sided, Mann–Whitney U-test). c, d Effect of local
administration of SAP on survival (c) and lung CFU (d) after i.t. injection of 5 × 106 in wt mice treated with saline (50 µl/mouse; n= 13) or human SAP
(50 µg/50 µl/mouse; n= 12) 2 h after infection. ***P= 0.003 (Log-rank, Mantel-Cox test). c One experiment shown out of 2 performed with similar
results. d Each spot corresponds to a single mouse. Mean ± SEM of an independent experiment. **P= 0.008 (two-sided, Mann–Whitney U-test).
Table 1 Genotype distribution of APCS genotypes among cases of IPA and controls.
SNP rs# number Alleles: status Genotype, n (%)a P-valueb
A/A A/a a/a
rs2808661 G > A
Donor IPA 79 (71.2) 28 (25.2) 4 (3.6) 0.04
Controls 269 (72.3) 99 (26.6) 4 (1.1)
Recipient IPA 76 (68.5) 30 (27.0) 5 (4.5) 0.11
Controls 276 (74.2) 89 (23.9) 7 (1.9)
rs3753869 C > A
Donor IPA 66 (59.5) 37 (33.3) 8 (7.2) 0.04
Controls 261 (70.2) 99 (26.6) 12 (3.2)
Recipient IPA 72 (64.9) 36 (32.4) 3 (2.7) 0.67
Controls 213 (57.3) 147 (39.5) 12 (3.2)
SNP single nucleotide polymorphism, IPA invasive pulmonary aspergillosis.
aThe major and minor alleles are represented by the first and second nucleotides, respectively.
bP-values were calculated using the cumulative incidence method and compared using Gray’s test (two-sided). P-values are reported for the comparison between A/A+A/a and a/a.
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mice2,38 and humans39–47 suggests that PTX3 plays an essential
role in resistance against selected pathogens, in particular A.
fumigatus. SAP is produced in the liver whereas PTX3 is stored in
neutrophil granules and produced by macrophages as well as by
other cell types1,2. It is therefore likely that SAP and PTX3 exert
through different molecular mechanisms51 complementary
functions systemically and in peripheral tissues in antifungal
resistance.
In hematological patients, we found that BALF had sub-
stantially higher levels of SAP in IPA compared to controls, but
not peripheral blood. Moreover, in patients undergoing stem cell
transplantation, donor genetic variation was associated with
increased susceptibility to IPA. These results raise the interesting
possibility that a relevant source of SAP is represented by
hematopoietic progenitor cells. The liver is the major dominant
source of SAP7,9,10. However, local expression of SAP has been
reported in atherosclerosis56 and in fibrotic lesions10. By bioin-
formatics analysis, we found evidence of APCS gene expression in
human myelomonocytic progenitors, myeloid cells in acute cor-
onary syndromes and in sepsis and myeloid murine cells (Sup-
plementary Fig. 12a–f). Moreover, APCS was expressed in
monocytes in our own cohort of COVID-19 patients57 as assessed
by RNAseq (Supplementary Fig. 12f). Further studies are required
to define the relevant extrahepatic cellular source of SAP in
patients with IPA.
There are well-known risk factors that predispose to fungal
disease, particularly in immunocompromised and severely ill
patients, but these alone fail to convincingly explain the devel-
opment of infection in all patients. Several studies have reported
an expanding number of SNPs associated with IPA40,43,58. We
now demonstrate that SNPs in APCS also contribute to IPA via
molecular mechanisms influencing opsonisation and activation of
the complement cascade in response to fungal infection.
Although genetic variation in APCS has been evaluated in the
context of other diseases, including type 2 diabetes and poly-
neuroendopathic amyloidosis59, these are not acknowledged as
relevant conditions predisposing to IPA. Our analyses have
indeed confirmed a role for APCS SNPs in IPA that is indepen-
dent from clinical risk factors often associated with the infection
in the stem-cell transplantation setting, such as the development
of severe acute GVHD. These data may become relevant in the
clinical management of patients at-risk of IPA, since the identi-
fication of patients that may benefit the most from SAP-based
therapies may be possible.
Fig. 7 SNPs in APCS predispose stem-cell transplant recipients to IPA. a, b Cumulative incidences of IPA according to APCS genotypes (IFIGEN cohort) are
shown. a Cumulative incidence according to donor or recipient rs2808661 genotypes: donor GG (22.8%, n= 348, reference), GA (21.4%, n= 127; P=0.67)
and AA (55.6%, n= 8; P=0.04), and recipient GG (20.3%, n= 352, reference), GA (25.0%, n= 119; P=0.58) and AA (36.4%, n= 12; P=0.08).
b Cumulative incidence according to donor or recipient rs3753869 genotypes: donor CC (20.6%, n= 327, reference), CA (25.9%, n= 136; P=0.30) and AA
(42.9%, n= 20; P=0.03), and recipient CC (23.4%, n= 285, reference), CA (20.4%, n= 183; P=0.59) and AA (18.2%, n= 15; P= 0.41). Data were
censored at 24 months, and relapse and death were competing events. a, b P-values are for Gray’s test (two-sided). c Levels of SAP in sera (left) and BALFs
(right) of hematological patients from the FUNBIOMICS cohort. Sera, controls, n= 14; IPA, n= 20. BALFs, n= 7; IPA, n= 9. Mean ± SEM. ***P=0.0007
(two-sided, Mann–Whitney U-test). d, e Levels of SAP in serum of IPA patients with donor rs2808661 (d) and donor rs3753869 (e). Donor rs2808661, GG
(n= 12), GA (n= 3), AA (n= 4) (d) and Donor rs3753869, CC (n= 13), CA (n= 3), AA (n= 4) (e) analyzed separately for the different genotype (d, e, left)
or AA vs. GG+GA (d, right) and AA vs. CC+CA (e, right). AA vs. GA, ***P=0.0006 (two-sided, unpaired t-test); AA vs. GG+GA, *P=0.05 (two-sided,
Mann–Whitney U-test); AA vs. CC, *P=0.03 (two-sided, unpaired t-test); AA vs. CC+CA, *P= 0.02 (two-sided, unpaired t-test). c–e, Mean ± SEM.
Table 2 Multivariate analysis of the association of APCS
SNPs with the risk of IPA among transplant recipients.
Genetic/clinical variables Adjusted HRa (95% CI) P-value
Donor AA genotype in rs3753869 3.59 (1.54–8.78) 0.012
Unrelated donor 1.98 (1.04–3.91) 0.041
Acute GVHD grades III–IV 2.37 (1.29–3.55) 0.006
Multivariate analyses were based on the subdistribution regression model of Fine and Gray.
HR hazard ratio, CI confidence interval.
aHazard ratios were adjusted for patient age and gender, type of transplantation, acute GVHD
III–IV and antifungal prophylaxis. Only the variables remaining significant after adjustment are
shown. The P-values are two-sided and no corrections for multiple testing were performed.
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The frequency of APCS homozygous mutant genotypes asso-
ciated with IPA is relatively low in the population. However, this
fact further strengthens the critical role of these genetic variants
as risk factors for IPA, since carriers of these genotypes reach
cumulative incidence values of infection around 50%. Therefore,
although rare in the general population, specific APCS genotypes
are greatly enriched among IPA patients, suggesting a particularly
relevant mechanism in the pathogenesis of infection, thus sup-
porting a potential clinical applicability for screening donors, for
patient management, e.g., to direct antifungal prophylaxis or to
intensify fungal diagnostics in patients at higher genetic risk.
SAP has been shown to regulate matrix deposition by reg-
ulating macrophages, which play a key role as orchestrators of
tissue remodeling10,31–33. These preclinical results paved the way
to clinical development of SAP (PRM-151) as an anti-fibrotic
agent34,35. Early Phase II results of PRM-151 in idiopathic pul-
monary fibrosis are encouraging36,37. Current therapeutic lim-
itations as well as concerns over the emergence of antifungal
resistance are inspiring the search for novel host-directed thera-
pies. The results reported here suggest that SAP may be explored
as a therapeutic agent in Aspergillus infections, which represent a
formidable clinical challenge.
Methods
Animals. Wild-type (wt) C57BL/6J and C57BL/6NJ mice between 8 and 10 weeks
of age were, respectively, purchased from Charles River Laboratories (Calco, Como,
Italy) and from The Jackson Lab (Bar Harbor ME, US). Apcs−/− mice were gen-
erated as described27. C1q−/− mice were kindly provided by Prof. John Lambris
(University of Pennsylvania, USA). C3−/−, Mbl1/2−/− and Fb−/− mice were
purchased from Jackson Lab (Bar Harbor ME, US). Apcs−/−, C1q−/−, C3−/−,
Mbl1/2−/− mice were on a C57BL/6J genetic background, whereas Fb−/− mice
were on C57BL6/NJ. wt littermates were used as control for Mbl1/2−/−, C1q−/−
and Fb−/− mice. Co-housed wt were used as control for C3−/−mice. Mice were
housed and bred in the SPF animal facility of Humanitas Clinical and Research
Center in individually ventilated cages (light-dark cycle: from 7 a.m. to 7 p.m.;
temperature and humidity: 20–24 °C and 40–60%). Procedures involving animals
and their care were conformed to protocols approved by the Humanitas Clinical
and Research Center (Rozzano, Milan, Italy) in compliance with national (4D.L.
N.116, G.U., suppl. 40, 18-2-1992) and international law and policies (EEC Council
Directive 2010/63/EU, OJ L 276/33, 22-09-2010; National Institutes of Health
Guide for the Care and Use of Laboratory Animals, US National Research Council,
2011). The study was approved by the Italian Ministry of Health (approval n. 71/
2012-B, issued on the 09/03/2012, 44/2015-PR issued 28/01/2015 and 742/2016-PR
issued on the 26/07/2016). All efforts were made to minimize the number of
animals used and their suffering.
Population cohorts. For the genetic association study, a total of 483 hematological
patients of European ancestry undergoing allogeneic HSCT at Instituto Português
de Oncologia, Porto, and at Hospital de Santa Maria, Lisbon (Portugal), were
enrolled in the IFIGEN study between 2009 and 2015. The demographic and
clinical characteristics of the patients are summarized in Supplementary Table 1.
One hundred-eleven cases of probable/proven IPA were identified according to the
2008 criteria from the European Organization for Research and Treatment of
Cancer/Mycology Study Group (EORTC/MSG)60. Twenty-one patients were
excluded from the study based on the “possible” classification of infection. The
levels of SAP were measured in clinical specimens from adult hematological
patients enrolled in the FUNBIOMICS study53 at the Leuven University Hospitals,
Leuven (Belgium). Cases of probable/proven IPA were diagnosed as above60. The
control group included patients with no evidence for the presence of Aspergillus
spp. in the bronchoalveolar lavage (BALF) sample (negative culture, negative
microscopy, and a galactomannan optical density index <0.5). Patients with
“possible” disease were excluded from the study and no mold-active antifungals
were administered by the treating physician(s) before sample collection. BALF and
serum samples were collected using standard protocols, as described53.
Ethics statement. Approval for the IFIGEN study was obtained from the Ethics
Committee for Research in Life and Health Sciences (CEICVS) of the University of
Minho, Portugal (no. 125/014), the Ethics Committee for Health of the Instituto
Português de Oncologia - Porto, Portugal (no. 26/015), the Ethics Committee of the
Lisbon Academic Medical Center, Portugal (no. 632/014), and the National
Commission for the Protection of Data, Portugal (no. 1950/015). The FUNBIO-
MICS study was approved by CEICVS and the Ethics Committee of the University
Hospitals of Leuven, Belgium (no.126/014). Written informed consent was
obtained from the patient or a representative prior to collection of samples.
The study on COVID-19 patients was approved by the local Humanitas Clinical
and Research Center Ethical Committee (authorization 233/20). This study was
conducted as described57 on a cohort of patients admitted to Humanitas Clinical
and Research Center (Rozzano, Milan, Italy) with a laboratory-confirmed diagnosis
of COVID-19.
In healthy donors, neutrophils and monocytes were isolated from peripheral
blood upon approval by the Humanitas Research Hospital Ethical Committee
(approval obtained on January 28th, 2016).
Invasive pulmonary aspergillosis. A clinical strain of A. fumigatus was isolated
from a patient with a fatal case of pulmonary aspergillosis was kindly provided by
Dr. Giovanni Salvatori (Sigma-tau, Rome, Italy). A. flavus (#MCV-C#1; ATCC®
204304) and A. terreus (Thom, #MF4833; ATCC® 20541) were purchased from
ATCC®. The growth and culture conditions of A. fumigatus, A. flavus and A.
terreus conidia were as described38. The Candida albicans strain CAF3-1 was
kindly provided by Dr. Marina Vai (Dept. of Biotechnology and Biosciences,
University of Milano-Bicocca). C. albicans blastospores were grown at 25 °C in rich
medium [YEPD (yeast extract, peptone, dextrose), 1% (w/v) yeast extract, 2% (w/v)
Bacto Peptone, and 2% (w/v) glucose] supplemented with uridine (50 mg/l) and the
hyphae induced as described61. For intratracheal (i.t.) injection, mice were anes-
thetized with ketamine (100 mg/kg; i.p.) and xylazine (10 mg/kg i.p.). After surgical
exposure, a volume of 50 μl PBS2+, pH 7.4, containing 1 × 108 or 5 × 107 resting
conidia (>95% viable, as determined by serial dilution and plating of the inoculum
on Sabouraud dextrose agar) were delivered into trachea under direct vision using a
catheter connected to the outlet of a micro-syringe (Terumo, Belgium). Survival to
infection was daily monitored for 10d later. C. albicans blastospores (5 × 106 in a
final volume of 50 μl PBS) were intravenously (i.v.) injected and survival monitored
for 20 days. Dying mice were euthanized after evaluation of the following clinical
parameters: body temperature dropping, intermittent respiration, solitude pre-
sence, sphere posture, fur erection, non-responsive alertness, and inability to ascent
when induced.
In experiments of in vivo phagocytosis, mice were i.t. injected with 5 × 107 heat-
inactivated fluorescein isothiocynate (FITC)-labeled conidia and euthanized 4 h
later. In rescue experiments, conidia (1 × 109) were opsonized with murine
recombinant SAP (50 µg/ml; lot. #MPX1518061; R&D Systems) for 1 h at r.t. in
PBS, pH 7.4, containing 0.01% (vol/vol) Tween-20® (Merck-Millipore). After
washing of unbound protein, a volume of 50 µl (5 × 107 conidia) was i.t. injected.
Alternatively, a single i.v. injection of murine SAP (50 µg/mouse; lot.
#MPX1518061; R&D Systems) previously dialyzed in PBS (pH 7.4) in order to
eliminate sodium azide was given after 2 h i.t. injection of conidia (5 × 107). In
therapy experiments, immunosuppression was induced by i.p. injection of 150 mg/
kg cyclophosphamide (150 µl per mouse of 20 mg/ml solution) 2 days before
infection and indicated doses of conidia were i.t. injected. Native human SAP (lot.
#2787319; Merck-Millipore) was dialyzed in PBS (pH 7.4) and i.p. injected at the
dose of 4 mg/kg at 2 and 24 h after infection. In experiments of local therapy, 50 µg
human SAP (1 mg/ml; 50 µl in PBS) were i.t. administred 2 h after infection.
BALFs collection and analysis. BALFs were performed with 1.5 ml PBS, pH 7.4,
containing protease inhibitors (Complete tablets, Roche Diagnostic; PMSF, Sigma-
Aldrich/Merck) and 10 mM EDTA (Sigma-Aldrich/Merck) with a 22-gauge venous
catheter. BALFs were centrifuged, and supernatants were collected for quantifica-
tion of cytokines as described below. After erythrocyte lysis with ACK solution (pH
7.2; NH4Cl 0.15 M, KHCO3 10mM, EDTA 0.1 mM), cells were resuspended in
PBS, pH 7.4, containing 10 mM EDTA and 1% heat-inactivated fetal bovine serum
(FCS; Sigma-Aldrich/Merck), stained with LIVE/DEAD™ Fixable Violet Dead Cell
Stain Kit (ThermoFisher Scientific-Molecular Probes) or Zombie Aqua™ Fixable
Viability Kit (Biolegend, US), and analyzed as reported in Supplementary Fig. 13 by
BD FACS LSRFortessaTM Flow Cytometer (BD Biosciences) and BD FACSDivaTM
Software (version 6.2) with the following specific antibodies: peridinin chlorophyll
protein complex (PerCP)- or brilliant violet (BV) 650-labeled anti-CD45 (#30-F11,
IgG2B; used at 4 µg/ml; Cat. No. 103130, Biolegend, and Cat. No. 563410, BD
Biosciences, respectively); FITC- or phycoerythrin (PE)-CF594-labeled anti-Ly6G
(#1A8, IgG2A; used at 4 µg/ml; Cat. No. 11-9668-82, eBioscience-Invitrogen, and
Cat. No. 562700, BD Biosciences, respectively); allophycocyanin (APC)-cyanine
(Cy)7- or BV421-labeled anti-CD11b (#M1/70, RUO, IgG2B; used at 1 µg/ml; Cat.
No. 557657 and Cat. No. 562605, BD Biosciences); BV421-labeled anti-Ly6C (#AL-
21, RUO, IgM; used at 1.6 µg/ml; Cat. No. 562727, BD Biosciences), APC-labeled
anti-CD11c (#HL3, IgG1; used at 1.6 µg/ml; Cat. No. 550261, BD Biosciences) and
PE-Cy7-labeled anti-F4/80 (#BM8, IgG2A; used at 1.6 µg/ml; Cat. No. 123110,
Biolegend). At least 10,000 events of CD45+ cells were considered as cut-off for the
the FACS analysis.
Lung homogenates and analysis. Lungs were removed 16 h after infection and
homogenized in 1 ml PBS, pH 7.4, containing 0.01% (vol/vol) Tween-20® (Merck-
Millipore) and protease inhibitors. Samples were serially diluted 1:10 in PBS and
plated on Sabouraud dextrose agar for blinded CFU counting. For lysate pre-
paration, lungs were collected at 4 h and homogenized in 50 mM Tris-HCl, pH 7.5,
containing 2 mM EGTA, 1 mM PMSF, 1% Triton X-100 (all from Sigma-Aldrich/
Merck), and complete protease inhibitor cocktail. Total proteins were measured by
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DC Protein Assay, according to manufacturer’s instructions (Bio-Rad Labora-
tories). Western blot analysis for C3 was performed after loading 10 µg of lung
protein extracts on sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE). The goat polyclonal anti-C3 (diluted 1:3000; Merck-Millipore, Cat.
No. 204869) and HRP-conjugated donkey anti-goat IgG (diluted 1:5000; R&D
Systems, Cat. No. HAF-109) were used. The monoclonal anti-vinculin (#hVIN-1;
used at 0.5 µg/ml; Sigma-Aldrich/Merck, Cat. No. V9264) was used as loading
control. C3d bands were quantified by Fiji-ImageJ (NIH, Bethesda USA; version
2.1.0/1.53.c) as a ratio of mean gray intensity values of each protein relative to
vinculin bands.
Cells and in vitro phagocytic activity. Phagocytosis assay in whole blood of A.
fumigatus conidia by mouse and human neutrophils was performed as described51.
Briefly, conidia (1 × 109) were labeled (1 h, r.t.) with FITC (Sigma-Aldrich/Merck;
5 mg/ml in DMSO), and eventually opsonized (1 h, r.t) with murine or human SAP
(100 µg/ml; 1.1 µM) and PTX3 (50 µg/ml; 1.1 µM). An amount of 1 × 107 FITC-
conidia were added to 200 µl of mouse whole blood (collected with heparin from
cava vein) and incubated for 1 and 20 min at 37 °C in an orbital shaker. Samples
were immediately placed on ice and ACK lysis solution was added to lyse ery-
throcytes. Murine neutrophils, monocytes, macrophages and dendritic cells were
analyzed by BD FACS LSRFortessaTM Flow Cytometer (BD Biosciences) as above
described and indicated in Supplementary Fig. 13, and frequency and/or mean
fluorescence intensity (MFI) of FITC+ neutrophils and/or CD11b expression were
reported.
Human neutrophils were isolated from fresh whole blood of healthy volunteers
through separation from erythrocytes by 3% dextran (GE Healthcare Life Sciences)
density gradient sedimentation followed by Ficoll-Paque PLUS (GE Healthcare Life
Sciences) and 62% Percoll® (Sigma-Aldrich/Merck) centrifugation as previously
described51. Blood monocytes were obtained by Ficoll-Paque PLUS (GE Healthcare
Life Sciences) and 46% Percoll® (Sigma-Aldrich/Merck). Purity, determined by
FACS analysis on forward scatter/side scatter parameters, was routinely > 98%. 1 ×
105 cells were incubated for 1 and 30 min at 37 °C in 50 µl RPMI-1640 medium
with 5 and/or 10% normal human serum (NS) or complement depleted sera,
optionally with autologous human plasma-heparin, and 1 × 106 FITC-labeled
A. fumigatus conidia. When indicated, cells were resuspended in 10% normal
plasma-heparin from healthy donors depleted from IgGs or SAP as described
below. Cells were transferred on ice and, after washing with PBS, pH 7.4,
containing 10 mM EDTA and 0.2% bovine serum albumin (BSA; Sigma-Aldrich/
Merck), FITC fluorescence in neutrophils (defined as FSC-Ahigh/SSC-Ahigh) and
monocytes (defined as FSC-Adim/SSC-Adim) was analyzed by BD FACS CantoTM II
Flow Cytometer (BD Biosciences) and BD FACSDivaTM Software (version 6.1.1).
NS and sera depleted of C3, C1q, MBL, FB and FH were all obtained from
CompTech (Complement Technology, Inc., USA). In blocking experiments,
neutrophils were-preincubated for 1 h on ice in the presence of following mouse
IgG1 (used at 10 µg/ml/1 × 106 cells): anti-CD16 (FcγRIII) (#3G8; BioLegend, Cat.
No. 302002); anti-CD32 (FcγRII) (#FUN-2; BioLegend, Cat. No. 303202), or anti-
CD32 (FcγRII) (#AT10; Merck-Millipore, Cat. No. MABF925); anti-CD64 (FcγRI)
(#10.1; eBioscience-ThermoFisher, Cat. No. 14-0649-82); anti-M-ficolin (#036-051
1; Santa Cruz Biotechnology, Cat. No. sc-80486); L-ficolin (#FCN219; Santa Cruz
Biotechnology, Cat. No. sc-80484); irrelevant mouse IgG1 (#MG1-45, BioLegend,
Cat. No. 401402, or #P3.6.2.8.1, ThermoFisher Scientific, Cat. No. 16-4714-82). All
these antibodies were previously dialyzed in PBS, pH 7.4.
Bone marrow-derived (BM) cells were isolated from femurs and tibiae and
cultured at density of 1.5 × 106 cells/ml in RPMI-1640 medium supplemented with
10% heat-inactivated Fetal Bovine Serum (FBS; Sigma-Aldrich/Merck), 2mM L-
Glutammine, 1% Pen/Strept for 24 h. Non-adherent cells were then harvested and
cultured with 20 ng/ml of murine recombinant M-CSF (PeproTech) to obtain
macrophages. Cells were washed and medium replaced at day 3. BM macrophages
(1 × 106 cells/ml) were stimulated on day 6 with heat-inactivated A. fumigatus
conidia (ratio 1:5, cell:conidia) or 10 ng/ml LPS (Sigma-Aldrich/Merck) in the
presence of 10% freshly isolated serum obtained from wt and Apcs−/− mice to
preserve functions of complement. Cell supernatants were collected (24 h) for
cytokine measurement.
Complement deposition on Aspergillus fumigatus. A volume of 10 µl PBS, pH
7.4, containing 1 × 107 conidia eventually opsonized with murine SAP (100 µg/ml
per 1 × 109 conidia, 1 h at r.t.) was incubated (37 °C) in round bottom wells of
Corning® 96-well polypropylene microplates for the indicated time points with
20 µl mouse plasma-heparin or 20 µl human NS, complement depleted sera
(diluted in PBS at 10% and 30%). When indicated, plasma-heparin obtained from
healthy donors depleted of IgGs or SAP (diluted in PBS at 10%) was used.
Complement deposition was blocked by addition of EDTA (10 mM final con-
centration) and by cooling in ice. After centrifugation (1450 x g, 10 min at 4 °C),
when indicated, supernatant was collected for mouse C5a measurement by ELISA.
Conidia were washed and incubated (1 h, at 4 °C) with PBS, pH 7.4, 2 mM EDTA,
1% BSA containing the following primary antibodies: goat anti-human/mouse C3
and activation fragments (diluted 1:5000; Merck-Millipore, Cat. No. 204869); rat
anti-mouse C1q (IgG1, #7H8; used at 1 µg/ml; HyCult® Biotech, Netherlands, Cat.
No. HM1044); rabbit anti-human C5b-C9 (MAC) (diluted 1:2000; Complement
Technology, Inc., Cat. No. A227); or correspondent irrelevant IgGs. Conidia were
then incubated (1 h, at 4 °C) with Alexa Fluor® 488 and 647-conjugated species-
specific cross-adsorbed detection antibodies (used at 2 µg/ml; ThermoFisher
Scientific-Molecular Probes, Cat. No. A-11055, A-48272, A-21206) and analyzed by
BD FACS CantoTM II Flow Cytometer (BD Biosciences) using forward and side
scatter parameters to gate at least 8000 conidia. After each step, conidia were
extensively washed with PBS, pH 7.4, 2 mM EDTA, 1% BSA. Results were
expressed as frequency of conidia showing fluorescence compared with irrelevant
controls and as geometric conidia MFI.
Fungal viability assay. Effect of SAP on A. fumigatus killing was evaluated by a
resazurin-based cell viability assay. A volume of 10 µl PBS, pH 7.4, containing 1.5 ×
105 conidia eventually opsonized with human SAP (100 µg/ml per 1 × 109 conidia,
1 h at r.t.) was placed into sterile round bottom Corning® 96-well polypropylene
microplate and incubated for 1 and 30 min at 37 °C with 20 µl of human serum and
different complement component-depleted sera (30%). After incubation, plates
were immediately cooled on ice and cold-centrifuged (1450 x g, 10 min at 4 °C),
and then supernatant removed. Conidia not incubated with serum were used as a
negative control. Conidia treated with the fungicide drug Posaconazole (POC;
1 µM) were considered as positive control in the assay. Preparation of Alamar-
BlueTM Cell Viability Reagent and test was performed according with manu-
facture’s instructions (ThermoFisher Scientific-Invitrogen). A volume of 100 µl
AlamarBlueTM solution (10 µl of AlamarBlueTM reagent and 90 µl of Sabouraud
dextrose broth) was added to each well. After 17 h reaction at 37 °C, fluorescence
(excitation/emission at ≈530–560/590 nm) intensity was measured by microplate
reader SynergyTM H4 (BioTek, France). Results represent ratio of fluorescence
intensity values relative to those measured in negative controls. The actual killing of
fungi was controlled as CFU count.
Proteins. Recombinant murine SAP from mouse myeloma cell line NSO was used
(lot. #MPX1518061; R&D Systems). Native SAP from human serum was purchased
by Merck-Millipore (lot. #2787319). Recombinant murine PTX3 was purified from
supernatant of Chinese hamster ovary cells (ATCC®-CRL-12023) stably expressing
the protein, as described previously51. Purity of the recombinant protein was
assessed by SDS-PAGE followed by silver staining. Proteins contained <0.125
endotoxin units/ml as checked by the Limulus amebocyte lysate assay (BioWhit-
taker®, Inc.). SAP levels were measured in mouse plasma by ELISA (DuoSet ELISA;
R&D Systems) after collection of blood from the cava vein. Murine MPO was
measured in BALFs by ELISA (DuoSet ELISA; R&D Systems). Murine CXCL1,
CXCL2, TNF-α and IL-6 were measured in supernatants by ELISA (DuoSet ELISA;
R&D Systems) according with manufacturer’s instructions. Murine C5a was
measured either in plasma-heparin or in BALFs previously stored at −80 °C by
DuoSet ELISA (R&D Systems) maintaining EDTA (10 mM) throughout the assay
in order to stop the activation of the complement cascade. Human SAP was
measured in sera and BALFs of patients by ELISA (lot. #P105304, DuoSet ELISA;
R&D Systems) according with manufacturer’s instructions.
IgGs and SAP depletion. Plasma-heparin of healthy volunteers was collected in
BD Vacutainer® and maintened (1 h) on ice during procedures of depletion to
avoid the activation of the complement. IgG depletion was obtained by passing
human plasma-heparin (2 ml) on protein-G SepharoseTM Fast Flow (GE Health-
care, Sweden) column, as indicated by manufacturer’s instructions. Depletion of
SAP was obtained by passing plasma heparin (2 ml) of each donor through dif-
ferent columns of protein-G SepharoseTM Fast Flow (GE Healthcare, Sweden)
previously cross-linked with a purified rabbit polyclonal anti-SAP (1 mg/1 ml of
resin) (Merck-Millipore, Cat. No. 565191). Dimethyl pimelimidate (Sigma-Aldrich/
Merck) was used as cross-linking reagent. Bound proteins were eluted with 0.1 M
Glicine-HCl pH 2.8, concentrated with Vivaspin® 10,000 MWCO (Sartorius,
Germany) and titrated with the PierceTM Coomassie (Bradford) protein assay kit
(ThermoFisher Scientific). The actual depletion of SAP and IgGs was evaluated by
Western blot analysis after loading 1 µl/lane plasma-heparin on SDS-PAGE. Pro-
teins eluted from the anti-SAP column were also loaded to ascertain its capture.
The mouse monoclonal anti-SAP (used at 0.5 µg/ml; #910119; R&D Systems, Cat.
No. MAB1948) and HRP-conjugated sheep anti-mouse IgG (diluted 1:3000; GE
Healtcare, Sweden, Cat. No. NA931V) or a goat anti-human IgG (used at 1 µg/ml;
Jackson ImmunoResearch, Cat. No. 109-006-097) and HRP-conjugated anti-goat
IgG (diluted 1:5000; R&D Systems, Cat. No. HAF-109) were used to detect,
respectively, SAP and IgGs. The different intensity of SAP (or IgG) bands between
lanes Donor A–E vs. Donor A–E/IgG depleted (or SAP depleted) are due to steric
hindrance of antibody recognition, having SAP and IgG low chains similar
molecular weight.
Binding of SAP. Aspergillus conidia (1 × 108 CFU) were cultured 4 and 16 h under
static condition in Sabouraud medium to, respectively, allow conidia swelling and
germination. C. albicans blastospore, yeast and hypheae (1 × 107 CFU) were
obtained as described61. After washing with PBS2+, pH 7.4, containing 0.01%
(vol/vol) Tween-20® (Merck-Millipore), resting and swollen conidia or hyphae
were incubated (1 h, r.t.) with biotin-labeled murine SAP (R&D Systems) at con-
centrations ranging from 0.1 to 10 µg/ml in PBS2+, pH 7.4, containing 2% BSA
(Sigma-Aldrich/Merck). In competition experiments, human SAP or CRP (50 µg/
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ml; lot. #B68019; Merck-Millipore) or murine PTX3 (50 µg/ml) were further added.
After extensive washing, samples were incubated (30 min, r.t.) with Alexa Fluor®
647-conjugated streptavidin (diluted 1:1000; ThermoFisher Scientific-Molecular
Probes, Cat. No. S-32357) and binding was evaluated by FACS as frequency and
MFI and visualized by confocal microscopy as described. In some experiments, a
rat monoclonal anti-SAP (IgG2A, #300103; used at 5 µg/ml; R&D Systems, Cat. No.
MAB2558) and an Alexa Fluor® 647-conjugated goat anti-rat IgG (diluted 1:500;
ThermoFisher Scientific-Molecular Probes, Cat. No. A21247) were also used. CRP
was cross-linked with BS3 (Bis[sulfosuccinimidyl]suberate; Thermo Fisher Scien-
tific) according to the manufacturer’s instructions.
Microscopy. Five micrometer cryostat sections of mouse lungs injected with 5 ×
107 heat inactivated FITC-labeled conidia (4 h) were incubated in 5% of normal
donkey (Sigma-Aldrich/Merck) serum, 2% BSA (Sigma-Aldrich/Merck), 0.1%
Triton X-100 (Sigma-Aldrich/Merck) in PBS2+, pH 7.4, (blocking buffer) for 1 h at
room temperature. Sections were incubated with the following primary antibodies
diluted in blocking buffer for 2 h at r.t.: rabbit polyclonal anti-SAP (diluted 1:500;
Merck-Millipore, Cat. No. 565191); rat monoclonal Ab anti-C3 (C3b/iC3b/C3d)
(IgG2A, #2/11; used at 5 µg/ml; Hycult® Biotech, Cat. No. HM1065) previously
conjugated with Alexa Fluor® 647 through the Antibody Labeling kit (Thermo-
Fisher Scientific-Molecular Probes) and BV421-labeled anti-Ly6G (IgG2A, #1A8;
used at 1 µg/ml; BD Biosciences, Cat. No. 562737). Sections were then incubated
for 1 h with an anti-rabbit IgG Alexa Fluor® 532-conjugated detection antibody
(used at 1 µg/ml; ThermoFisher Scientific-Molecular Probes, Cat. No. A-11009).
After each step, sections were washed with PBS2+, pH 7.4, containing 0.01% (vol/
vol) Tween-20® (Merck-Millipore). Correspondent IgG isotype controls (BV421-
and Alexa Fluor® 647-labeled rat IgGs from BD Biosciences, respectively, Cat. No.
562602 and 557690, and a purified homemade rabbit IgG) were used. Lungs
obtained from Apcs−/− mice were used as control. Sections were mounted with the
antifade medium FluorPreserve® Reagent (Merck-Millipore) and analyzed in a
sequential scanning mode with a Leica TCS SP8 confocal microscope at Airy Unit 1
(pinhole aperture 95.5 µm) with an oil immersion lens HC PL APO 63X (N.A. 1.4)
equipped with Leica Application Suite X software (LASX; version 3.5.5.19976).
Images of SAP binding to resting or germinated conidia were obtained after z-stack
acquisition using same instrument parameters and image deconvolution by Huy-
gens Professional software (Scientific Volume Imaging B. V.; version 19.10) and
presented as medium intensity projection (MIP).
SNP selection and genotyping. Genomic DNA was isolated from whole blood of
patients enrolled in the IFIGEN study using the QIAcube automated system
(Qiagen). SNPs were selected based on their ability to tag surrounding variants
with a pairwise correlation coefficient r2 of at least 0.80 and a minor allele fre-
quency ≥5% using publically available sequencing data from the Pilot 1 of the 1000
Genomes Project for the CEU population. Supplementary Table 3 reports
sequences of the primers used in the study. Genotyping was performed using
KASPar assays (LGC Genomics) in an Applied Biosystems 7500 Fast Real-Time
PCR system (Thermo Fisher Scientific), according to the manufacturer’s instruc-
tions. Mean call rate for the SNPs was > 98%. Quality control for the genotyping
results was achieved with negative controls and randomly selected samples with
known genotypes.
In silico data analysis. Publicly available expression data relative to human and
murine myeloid cells were retrieved from the open access platform Gene Expression
Omnibus archive (GEO). Data relative to human mononuclear BM cells were
retrieved from the GEO data series GSE4251962,63 based on Affymetrix Human
Genome U133 Plus 2.0 Array. In this experiment, mononuclear BM cells from
heathly donors were enriched for CD34+ and hematopoietic stem and progenitor
cells were sorted by FACS. Hematopoietic stem cells (HSCs) and hematopoietic
progenitors (HPCs) with the following immunophenotypes were purified as
described using a BD FACS Aria ITM cell sorter (BD Bioscience): HSCs, Lin− CD34
+ CD38− CD90+ CD45RA−; multipotent progenitors, Lin−, CD34+, CD38− CD90
− CD45RA-; common myeloid progenitors, Lin− CD34+ CD38+ CD45RA− CD123
+; megakaryocyte-erythroid progenitors, Lin− CD34+ CD38+ CD45RA− CD123−;
granulocyte-macrophage progenitors, Lin− CD34+ CD38+ CD45RA+ CD123+.
BM populations representing early and late promyelocytes, myelocytes, metamye-
locytes, band cells, and BM polymorphonuclear cells were isolated by flow
cytometry-based cell sorting: early promyelocytes, Lin− FSChi SSCint CD34−
CD15int CD49dhi CD33hi CD11b− CD16−; late promyelocytes, Lin− FSChi
SSChi CD34− CD15hi CD49dhi CD33hi CD11b− CD16−; myelocytes, Lin− FSChi
SSChi CD34− CD15hi CD49dhi CD33hi CD11bhi CD16−; metamyelocytes, Lin−
FSChi SSChi CD34− CD15hi CD49d− CD33− CD11bhi CD16−; band cells, Lin−
FSChi SSChi CD34− CD15hi CD49d− CD33− CD11bhi CD16int; polymorpho-
nuclear cells, Lin− FSChi SSChi CD34− CD15hi CD49d− CD33− CD11bhi CD16hi.
Data relative to monocytes and macrophages derived from patients affected by acute
coronary syndrome were obtained from the GEO data series GSE1143064 based on
Affymetrix Human Genome U133 Plus 2.0 Array. In this study, blood samples were
obtained from patients with symptoms of acute coronary syndrome who had
undergone coronary angiography and who had one stenosis > 50% diagnosed in at
least one major coronary artery. RNA samples were extracted from monocyte and
monocyte derived macrophages. Data relative to human neutrophils were obtained
from the GEO data series GSE303765 based on Affymetrix Human Genome U133A
Array. Peripheral blood neutrophils were isolated from septic patients and treated
in vitro with LPS or HMGB1. Since no raw data were available, data were processed
starting with the gene expression matrix. Expression data of murine macrophage
were obtained from the GEO data series GSE293566. Mouse macrophage cultures
were obtained from PBMCs isolated from wt mice inoculated with Sendai virus
(SeV) or UV-inactivated SeV (UV-SeV). Expression was evaluated with Affymetrix
Murine Genome U74A Version 2 Array. Since no raw data were available, data were
processed starting with the gene expression matrix. Data of murine neutrophils were
obtained from the GEO series GSE2521167 based on Illumina MouseRef-8 v2.0
expression beadchip array. In this study, transcriptional differences of neutrophils
isolated from wt and Il-1r1−/− mice after treatment with Ikkβ inhibitors were
measured by Illumina MouseRef-8 v2.0 expression beadchip array. All microarray
transcriptional data were processed starting with raw files when available, using R
statistical environment (version 3.5.2) with the R packages “Biobase” version 2.42.0),
“GEOquery” (version 2.50.5). Normalization, probes annotation, gene summariza-
tion and differential expression significance assessments were performed with the R
package Limma (version 3.38.3). Bulk RNA-Seq data of human peripheral mono-
cytes of COVID-19-infected patients and healthy controls were obtained from the
GEO series GSE16035157. Associated transcriptomic data of human peripheral
neutrophils derived from the same healthy donor samples were generated using
same sequencing technology and protocols57. Briefly, RNA from neutrophils iso-
lated from whole blood by negative selection using MACSxpress® Whole Blood
Neutrophil Isolation Kit (Miltenyi Biotec, Germany) was purified with the Direct-
zol RNA Microprep or Miniprep Kits (Zymo Research), according to manu-
facturer’s instructions. Total-RNA-sequencing library preparation was performed
starting from 1 ng of total-RNA with the SMART-Seq Stranded Kit (Clontech-
Takara). Libraries obtained were qualitatively assessed by using TapeStation 4200
(Agilent) and quantified by Qubit Fluorimeter (Thermofisher). Afterwards, they
were multiplexed in equimolar pools and sequenced on a NextSeq-550 Illumina
Platform generating at least 80 million 75bp-PE reads per sample. Raw RNA-Seq
data of human peripheral neutrophils derived from three healthy donors are
deposited and publicly available under the GEO series GSE163533. Raw files were
aligned and quantified with STAR (version 2.6.1) on the GRCh38 genome guided by
GENCODE annotation (version 33). Gene summarized counts were processed in R,
genes whose expression was minor than two reads were removed while the
remaining portion was “vs. normalized” with the R package DESeq268 (version
1.22.1). Plots were rendered with the R library “ggplot2” (version 3.3.2).
Statistic. Student’s t-tests were performed after data were confirmed to fulfill the
criteria of normal distribution and equal variance. Otherwise Mann–Whitney test
was applied. Log-rank (Mantel-Cox) test was performed for comparison of survival
curves. Statistical significance of multivariate frequency distribution between
groups was also analyzed by Fisher’s Exact test. Analyses were performed with
GraphPad Prism version 6 or 7c software. The probability of IPA according to
APCS genotypes was determined using the cumulative incidence method and
compared using Gray’s test. Cumulative incidences of infection at 24 months were
computed with the cmprsk package for R version 2.10.1, with censoring of data at
the date of last follow-up visit and relapse and death as competing events. All
clinical and genetic variables achieving a P-value ≤ 0.15 in the univariate analysis
were entered one by one in a pairwise model together and kept in the final model if
they remained significant (P < 0.05). Multivariate analysis was performed using the
subdistribution regression model of Fine and Gray with the cmprsk package for R
version 2.10.1.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data needed to evaluate the conclusions in the paper are present in the paper and/or
in the Supplementary Information and Data Source File. Additional data related to this
paper may be requested from the authors. Source data are provided with this paper.
Code availability
Bioinformatic methods used for in silico analyses were based on publicly available
software, custom scripts might be requested to the authors. Microarray-based
computational analyses were performed on publicly available datasets derived from the
Gene Expression Omnibus (GEO) platform under the accession ID GSE42519,
GSE11430, GSE3037, GSE2935, GSE25211, retrieved following these links: RNA-Seq data
were derived from in-house performed sequencing experiments and are publicly available
under the accession ID GSE160351 and GSE163533.
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